TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10422040
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/day for 28 days
Study: 15823823
Drug: Sequential estrogen-progestogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential estrogen-progestogen therapy (0.625 mg CEE for 25 days + 5 mg MPA on days 16-25)
Study: 15823823
Drug: Sequential estrogen-progestogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential estrogen-progestogen therapy
Study: 11991622
Drug: rebamipide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: rebamipide (300 mg daily for 12 months)
Study: 9850405
Drug: Oral halofantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral halofantrine 8 mg/kg body weight every 6 h for 3 doses
Study: 2809856
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg daily for 1 week, followed by 3.4 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks
Study: 2809856
Drug: 3.4 g
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g daily of EPA and DHA for 4 weeks, followed by ASA 300 mg daily for 1 week
Study: 25294250
Drug: Oritavancin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin (single intravenous 1200-mg dose)
Study: 25294250
Drug: Vancomycin (7-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (7-10 days of twice-daily treatment)
Study: 9375539
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg methylprednisolone (MP)
Study: 7672489
Drug: Subcutaneous fast‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fast‐acting insulin
Study: 24693632
Drug: NaF-DL combination
Normalized name: DL-dimyristoylphosphatidylcholine
DrugBank: DL-dimyristoylphosphatidylcholine (DB11283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF-DL combination
Study: 24693632
Drug: HEMA-G (Gluma
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEMA-G (Gluma desensitizer)
Study: 21813162
Drug: warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin plus 75‐100 mg aspirin
Study: 21813162
Drug: warfarin only
Normalized name: Warfarin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin only
Study: 3830930
Drug: L-tryptophan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (1 g with 10 g of CHO, three times a day, 30 min before meals)
Study: 18391631
Drug: Chemotherapy regimens:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens: Methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine and cisplatin
Study: 11908598
Drug: Oleoresin capsicum
Normalized name: Oleoresin capsicum
DrugBank: Capsicum oleoresin (DB11131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleoresin capsicum (OC) spray inhalation
Study: 8585252
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean 4.8 mg) plus pethidin (50 mg)
Study: 8585252
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean 5.2 mg i.v.)
Study: 2615928
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of d-amphetamine sulfate
Study: 31331546
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum (St John's wort) 270‐330 μg tablets three times a day for two months
Study: 29950814
Drug: Verinurad 10
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 10 mg (multiple doses)
Study: 29950814
Drug: Verinurad (2.5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (2.5-15 mg, single and multiple doses)
Study: 22238097
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 4 mg of cortisol (hydrocortisone)
Study: 9636831
Drug: G-CSF (filgrastim)-supported
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (filgrastim)-supported FEC therapy (5-fluorouracil, epirubicin, and cyclophosphamide) with ciprofloxacin prophylaxis; nine courses q three weeks; six different FEC dose levels used for treatment.
Study: 2962005
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg daily)
Study: 29452970
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatments (CGC, CMC, HPG)
Study: 22510538
Drug: Morphine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (60 mg/day) + Pregabalin (25 mg/day to 150 mg/day over one week)
Study: 18026891
Drug: Risperidone (0.01-0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.01-0.08 mg/kg/day)
Study: 15345500
Drug: AZD3582 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 750 mg twice daily
Study: 16497612
Drug: AZD3582 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 750 mg daily
Study: 16497612
Drug: naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 250 mg twice daily
Study: 11119080
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (INO) at 4 ppm
Study: 11969277
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg intravenous bolus, then 40 mg subcutaneously every 8 h)
Study: 2756913
Drug: High-energy supplement
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy supplement
Study: 2756913
Drug: Low-energy supplement
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy supplement
Study: 5320587
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment with griseofulvin
Study: 5320587
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment with griseofulvin
Study: 31637971
Drug: Baseline albuminuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline albuminuria (≥30 mg/g) versus not
Study: 12457078
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for 28 days followed by 10 mg/day)
Study: 10749249
Drug: Fractal analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractal analysis of nuclear medicine images
Study: 3710634
Drug: Rapidly dissolving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly dissolving tablet (1.0 g)
Study: 3710634
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release product C (1.0 g)
Study: 3710634
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release product D (1.0 g)
Study: 29457540
Drug: High CD34+
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CD34+ cell dosage
Study: 6797863
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 40.3 ± 2.0 kcal.kg‐1.day‐1 (7.0 mg glucose.kg‐1.min‐1) and 0.27 ± 0.02 g N.kg‐1.day‐1
Study: 6797863
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 53.4 ± 6.8 kcal.kg‐1.day‐1 (9.2 mg glucose.kg‐1.min‐1) and 0.36 ± 0.05 g N.kg‐1.day‐1
Study: 29275370
Drug: Programmable Hypertension
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmable Hypertension Control (PHC) therapy activated after baseline measurements
Study: 18662829
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravitreal triamcinolone
Study: 17905097
Drug: Intravesical botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical botulinum toxin A (BTX‐A) injections (100 U or 200 U) followed by cystoscopic hydrodistension
Study: 17905097
Drug: Intravesical botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical botulinum toxin A (BTX‐A) injections
Study: 29141255
Drug: Nortriptyline (NOR)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NOR) 50-150 mg (mean dose 106.2, SD±8.2)
Study: 29141255
Drug: Venlafaxine (VEN)
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine (VEN) 75-225 mg (mean dose 181.3, SD±8.8)
Study: 23944720
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg QD plus PegIFN/RBV
Study: 23944720
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD plus PegIFN/RBV
Study: 23944720
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD plus PegIFN/RBV (treatment-experienced)
Study: 22357699
Drug: No CKD
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CKD (eGFR ≥ 60 mL/min)
Study: 24299019
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/day)
Study: 1691921
Drug: Cisplatin 120
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6
Study: 1691921
Drug: Cisplatin 120
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6 (for patients without dissemination)
Study: 1691921
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (for patients without dissemination)
Study: 19432567
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement (60 mg daily)
Study: 11840040
Drug: Interferon-alpha +
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha + Ribavirin (3 million U/m2 subcutaneous interferon-alpha three times weekly and 15 mg/kg oral ribavirin daily for 12 months)
Study: 11840040
Drug: Interferon-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (3 million U/m2 subcutaneous interferon-alpha three times weekly for 12 months)
Study: 23129180
Drug: Alfacalcidol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1.0 μg daily)
Study: 17477111
Drug: Drospirenone/estradiol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone/estradiol therapy
Study: 2205798
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (8.7 mumol or 8333 IU) and Vitamin E (46 mumol or 20 mg)
Study: 6788458
Drug: Ceftriaxone Ro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone Ro 13-9904, 250 mg
Study: 27554534
Drug: Rabivax-S (1mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabivax-S (1mL IM; five doses)
Study: 27554534
Drug: Rabivax-S (0.1mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabivax-S (0.1mL ID; eight doses)
Study: 27554534
Drug: Purified chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified chick embryo cell vaccine (PCEC, Rabipur®) (1mL IM; five doses)
Study: 9250846
Drug: Enoxaparin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (low-molecular-weight heparin)
Study: 17601186
Drug: Antiparkinsonian medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparkinsonian medication (presurgery dosage)
Study: 8135445
Drug: Slow-release sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release sodium fluoride (25 mg twice daily) with continuous calcium citrate (400 mg calcium twice daily)
Study: 8135445
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with continuous calcium citrate (400 mg calcium twice daily)
Study: 1093389
Drug: Bivalent measles-rubella
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent measles-rubella vaccine
Study: 31397969
Drug: Desmopressin ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin ODT 25 μg
Study: 31397969
Drug: Desmopressin ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin ODT 25 μg (females)
Study: 22415421
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with 40 mg/day of proton pump inhibitors (PPIs)
Study: 22415421
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Nissen fundoplication, NFP)
Study: 20306184
Drug: Pantoprazole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 2.5 mg (approx. 1.2 mg/kg)
Study: 2029014
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (500 mg three times a day) with low sodium diet
Study: 7024762
Drug: des‐phe‐mixed‐insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: des‐phe‐mixed‐insulin
Study: 7024762
Drug: Mixtard (highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixtard (highly purified insulin from pig)
Study: 24664788
Drug: 40% L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% L-menthol
Study: 24664788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-menthol and CA
Study: 1553769
Drug: Cololax regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cololax regimen (oral ingestion of electrolyte polyethylene glycol solution)
Study: 26011549
Drug: Tailored behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored behavioral pharmacist‐administered and telephone‐based intervention (CITIES)
Study: 26400431
Drug: Delphinol (maqui
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delphinol (maqui berry extract) 162 mg anthocyanins, taken 3 times daily for 4 weeks
Study: 17454589
Drug: IFNalpha‐2a, 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha‐2a, 9 MIU once daily
Study: 17454589
Drug: PEG‐IFNalpha‐2a, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNalpha‐2a, 450 microg once weekly
Study: 12414849
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d micronized E(2) (n = 12)
Study: 7857585
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and ridazolol (beta-adrenoreceptor blockers)
Study: 26
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Sch 1000
Study: 21981869
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules containing 3g of wheat flour each, taken morning and evening)
Study: 19019594
Drug: Oleoresin capsicum
Normalized name: Oleoresin capsicum
DrugBank: Capsicum oleoresin (DB11131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleoresin capsicum (O.C.) (5-s spray to the eyes)
Study: 15377853
Drug: Subjective burden
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective burden before adjuvant therapy
Study: 11865786
Drug: EMLA anesthetic
Normalized name: Emla Anesthetic Disc
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA anesthetic cream applied for 15 minutes
Study: 8163732
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg DMSA for 14 days
Study: 8163732
Drug: DMSA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSA treatment
Study: 2828406
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (20 mg/kg)
Study: 2828406
Drug: Cortisol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (0.1 mg/kg)
Study: 2828406
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 and cortisol combination
Study: 25840429
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 mcg) 1 hour prior to surgery
Study: 25840429
Drug: Administration route
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration route
Study: 19728565
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of 135 mg amodiaquine and 50 mg artesunate administered after a high-fat breakfast
Study: 19728565
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of 135 mg amodiaquine and 50 mg artesunate administered in fasting state
Study: 15705369
Drug: GnRH-agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-agonist
Study: 10201465
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg q.d. and metronidazole extended‐release formulation 750 mg q.d. for 10 days (OM)
Study: 10201465
Drug: OM plus
Normalized name: Childrens Multi-symptom Plus Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM plus clarithromycin 1 g q.d. for 10 days (OMCI)
Study: 7575985
Drug: Low air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low air loss (LAL) therapy
Study: 3102089
Drug: Ifosfamide (IFOS)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFOS) 5 g/m2
Study: 3102089
Drug: Cyclophosphamide (CYCLO)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYCLO) 1.5 g/m2
Study: 26331711
Drug: Pre-ESD eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ESD eradication therapy (n = 44)
Study: 26331711
Drug: Post-ESD eradication
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-ESD eradication therapy (n = 52)
Study: 12770651
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and postoperative administration of atenolol
Study: 10894377
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression (surgical treatment)
Study: 11567544
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (control group)
Study: 8336255
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid treatment (saturated, pH 1 for 3 minutes)
Study: 29193548
Drug: Pre-hospital blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital blood product (PHBP) administration (up to two units of red blood cells and two units of lyophilised plasma)
Study: 29193548
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (up to four boluses of 250 mL 0.9% saline)
Study: 9065279
Drug: Preoperative hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative hormone therapy
Study: 9065279
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative hormone therapy (Control)
Study: 1860293
Drug: Topical varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical varnish containing strontium chloride
Study: 28062251
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (0.7ng/ml target-controlled infusion)
Study: 25613351
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic nucleus (STN) DBS + Optimal Drug Therapy (ODT)
Study: 23083831
Drug: Dinoprostone intravaginal
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone intravaginal suppository
Study: 21457679
Drug: TAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU plus brief behavioral therapy for insomnia (4 weekly 1-hour sessions)
Study: 30153781
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care fluid administration
Study: 1518731
Drug: Ibuprofen 1800
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1800 mg/day for 6 days
Study: 31809216
Drug: AR19 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR19 20 mg
Study: 30722001
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 μg)
Study: 30722001
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL 0.9% saline)
Study: 22280352
Drug: 12 μg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 μg/die of vitamin K (G II)
Study: 22280352
Drug: Placebo (G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (G III)
Study: 20164823
Drug: Erythropoietin (high-dose);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (high-dose); administered based on biomarker levels above 46.3
Study: 18757324
Drug: Weight change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight change during adjuvant therapy
Study: 2142949
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) - 50 micrograms bolus, then 1 microgram/min infusion
Study: 26247145
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication administration
Study: 18344730
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d escitalopram
Study: 18344730
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d escitalopram
Study: 17089111
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate 2.4 mg/kg body weight